Analysts expect that Danaher Co. (NYSE:DHR) will announce $4.92 billion in sales for the current fiscal quarter, according to Zacks. Seven analysts have provided estimates for Danaher’s earnings. The highest sales estimate is $4.98 billion and the lowest is $4.77 billion. Danaher reported sales of $4.51 billion in the same quarter last year, which indicates a positive year-over-year growth rate of 9.1%. The firm is scheduled to announce its next earnings results on Thursday, July 19th.
On average, analysts expect that Danaher will report full year sales of $19.91 billion for the current financial year, with estimates ranging from $19.69 billion to $20.03 billion. For the next fiscal year, analysts forecast that the company will report sales of $20.84 billion per share, with estimates ranging from $20.68 billion to $21.04 billion. Zacks’ sales calculations are an average based on a survey of analysts that follow Danaher.
Danaher (NYSE:DHR) last released its quarterly earnings results on Thursday, April 19th. The conglomerate reported $0.99 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.94 by $0.05. The business had revenue of $4.70 billion during the quarter, compared to analysts’ expectations of $4.54 billion. Danaher had a return on equity of 11.39% and a net margin of 13.56%. The firm’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same period last year, the firm posted $0.85 EPS.
DHR has been the subject of several research reports. UBS initiated coverage on Danaher in a report on Monday, January 22nd. They set a “buy” rating and a $99.97 price target for the company. Cowen restated a “buy” rating and set a $110.00 price objective on shares of Danaher in a research note on Tuesday, January 30th. Credit Suisse Group raised their price objective on Danaher from $99.00 to $105.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 31st. Morgan Stanley raised their price objective on Danaher from $103.00 to $110.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 31st. Finally, Stifel Nicolaus raised their price objective on Danaher from $110.00 to $115.00 and gave the stock a “buy” rating in a research note on Wednesday, January 31st. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have given a buy rating to the company’s stock. Danaher has a consensus rating of “Buy” and a consensus price target of $105.56.
NYSE:DHR opened at $102.24 on Friday. The company has a market cap of $70.73 billion, a P/E ratio of 25.37, a PEG ratio of 1.90 and a beta of 1.03. The company has a quick ratio of 1.15, a current ratio of 1.59 and a debt-to-equity ratio of 0.38. Danaher has a 1-year low of $78.97 and a 1-year high of $104.82.
The firm also recently declared a quarterly dividend, which will be paid on Friday, July 27th. Stockholders of record on Friday, June 29th will be paid a $0.16 dividend. The ex-dividend date of this dividend is Thursday, June 28th. This represents a $0.64 annualized dividend and a dividend yield of 0.63%. Danaher’s payout ratio is 15.88%.
In other news, CFO Daniel L. Comas sold 78,379 shares of Danaher stock in a transaction on Monday, April 23rd. The stock was sold at an average price of $101.67, for a total value of $7,968,792.93. Following the transaction, the chief financial officer now owns 148,769 shares in the company, valued at approximately $15,125,344.23. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Rainer Blair sold 51,080 shares of Danaher stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $97.26, for a total value of $4,968,040.80. Following the completion of the transaction, the insider now owns 50,477 shares in the company, valued at approximately $4,909,393.02. The disclosure for this sale can be found here. In the last quarter, insiders sold 318,157 shares of company stock worth $31,990,824. Corporate insiders own 11.90% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the company. First Personal Financial Services increased its stake in shares of Danaher by 128.9% in the 4th quarter. First Personal Financial Services now owns 1,227 shares of the conglomerate’s stock valued at $114,000 after purchasing an additional 691 shares during the last quarter. Calton & Associates Inc. bought a new position in shares of Danaher in the 4th quarter valued at $114,000. CNB Bank bought a new position in shares of Danaher in the 4th quarter valued at $116,000. Truewealth LLC bought a new position in shares of Danaher in the 4th quarter valued at $121,000. Finally, Zions Bancorporation bought a new stake in Danaher during the 1st quarter worth $123,000. Institutional investors own 76.66% of the company’s stock.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides laser scanning, compound, surgical, and other stereo microscopes. This segment also offers filtration, separation, and purification technologies to the biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial sectors.
Get a free copy of the Zacks research report on Danaher (DHR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.